 A STUDY OF TRASTUZUMAB EMTANSINE TRASTUZUMAB-MCC-DM1, T-DM1 IN COMBINATION WITH PERTUZUMAB ADMINISTERED TO PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE PREVIOUSLY RECEIVED TRASTUZUMAB: 